(Q36066161)

12 August 2017

1 reference

title

Vaccination strategies for the prevention of cervical cancer (English)

1 reference

12 August 2017

main subject

cervix uterine cancer

1 reference

3

Anna-Lise Williamson

1 reference

12 August 2017

James Maclean

1

1 reference

12 August 2017

Edward P Rybicki

series ordinal

2

1 reference

12 August 2017

publication date

1 February 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

97-107

1 reference

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Classification of papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

21 January 2018

Human papillomaviruses.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Interactions between papillomavirus L1 and L2 capsid proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Production of human papillomavirus type 16 virus-like particles in transgenic plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Oral immunogenicity of human papillomavirus-like particles expressed in potato

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Evaluating human papillomavirus vaccination programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

The mucosal immune system: from fundamental concepts to vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Epidemiology of Genital Human Papillomavirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Genital human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Neoplastic conditions in the context of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

The induction of cytotoxic T-lymphocyte precursor cells by recombinant vaccinia virus expressing human papillomavirus type 16 L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Oral immunization with attenuated Salmonella expressing human sperm antigen induces antibodies in serum and the reproductive tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Immune response to cholera toxin epitope inserted in Salmonella flagellin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Immunogenicity of transgenic plant-derived hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Oral immunization with a recombinant bacterial antigen produced in transgenic plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

Transgenic Plants Created for Oral Immunization Against Diarrheal Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.97

21 January 2018

Identifiers

DOI

10.1586/14737140.5.1.97

1 reference

12 August 2017

1 reference